The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma

and on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The optimal treatment strategy with the use of hematopoietic stem cell transplantation (HSCT) for relapsed and refractory Hodgkin lymphoma (HL) remains unclear. We performed a retrospective analysis using registry data from the Japanese Society for Hematopoietic Cell Transplantation. Adult patients with HL who underwent a first autologous or a first allogeneic HSCT between 2002 and 2009 were included. Patients who underwent HSCT in first complete remission (CR) were excluded. Autologous and allogeneic HSCT were performed in 298 and 122 patients, respectively. For autologous HSCT, overall survival at 3 years (3yOS) was 70%, and sex, age, disease status, and performance status (PS) at HSCT were prognostic factors. OS was favorable even in patients who underwent autologous HSCT in disease status other than CR. For allogeneic HSCT, 3yOS was 43%, and sex and PS at HSCT were prognostic factors. Disease status at HSCT, previous autologous HSCT, and conditioning intensity did not affect OS. Moreover, graft-versus-host disease did not affect progression-free survival or relapse/progression rate. A first allogeneic HSCT without a previous autologous HSCT was performed in 40 patients. 3yOS was 45%, and was significantly inferior to that in patients who underwent their first autologous HSCT. This result was retained after the correction by the different patient characteristics according to the type of HSCT. In conclusion, autologous HSCT is effective in prolonging survival in patients with relapsed and refractory HL. Allogeneic HSCT might be beneficial even to relapsed HL after autologous HSCT, although establishing the role of allogeneic HSCT remains a challenge.

Original languageEnglish
Pages (from-to)132-138
Number of pages7
JournalAmerican Journal of Hematology
Volume90
Issue number2
DOIs
Publication statusPublished - 2015 Feb 1

Fingerprint

Hematopoietic Stem Cell Transplantation
Hodgkin Disease
Transplantation Conditioning
Survival
Cell Transplantation

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

and on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation (2015). The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. American Journal of Hematology, 90(2), 132-138. https://doi.org/10.1002/ajh.23897

The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. / and on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation.

In: American Journal of Hematology, Vol. 90, No. 2, 01.02.2015, p. 132-138.

Research output: Contribution to journalArticle

and on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation 2015, 'The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma', American Journal of Hematology, vol. 90, no. 2, pp. 132-138. https://doi.org/10.1002/ajh.23897
and on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. American Journal of Hematology. 2015 Feb 1;90(2):132-138. https://doi.org/10.1002/ajh.23897
and on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation. / The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. In: American Journal of Hematology. 2015 ; Vol. 90, No. 2. pp. 132-138.
@article{abd06339ba144bcf893dd20f6d537b3f,
title = "The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma",
abstract = "The optimal treatment strategy with the use of hematopoietic stem cell transplantation (HSCT) for relapsed and refractory Hodgkin lymphoma (HL) remains unclear. We performed a retrospective analysis using registry data from the Japanese Society for Hematopoietic Cell Transplantation. Adult patients with HL who underwent a first autologous or a first allogeneic HSCT between 2002 and 2009 were included. Patients who underwent HSCT in first complete remission (CR) were excluded. Autologous and allogeneic HSCT were performed in 298 and 122 patients, respectively. For autologous HSCT, overall survival at 3 years (3yOS) was 70{\%}, and sex, age, disease status, and performance status (PS) at HSCT were prognostic factors. OS was favorable even in patients who underwent autologous HSCT in disease status other than CR. For allogeneic HSCT, 3yOS was 43{\%}, and sex and PS at HSCT were prognostic factors. Disease status at HSCT, previous autologous HSCT, and conditioning intensity did not affect OS. Moreover, graft-versus-host disease did not affect progression-free survival or relapse/progression rate. A first allogeneic HSCT without a previous autologous HSCT was performed in 40 patients. 3yOS was 45{\%}, and was significantly inferior to that in patients who underwent their first autologous HSCT. This result was retained after the correction by the different patient characteristics according to the type of HSCT. In conclusion, autologous HSCT is effective in prolonging survival in patients with relapsed and refractory HL. Allogeneic HSCT might be beneficial even to relapsed HL after autologous HSCT, although establishing the role of allogeneic HSCT remains a challenge.",
author = "{and on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation} and Shinichi Kako and Koji Izutsu and Koji Kato and Kim, {Sung Won} and Takehiko Mori and Takahiro Fukuda and Naoki Kobayashi and Hirofumi Taji and Hisako Hashimoto and Tadakazu Kondo and Hisashi Sakamaki and Yasuo Morishima and Ritsuro Suzuki and Junji Suzumiya",
year = "2015",
month = "2",
day = "1",
doi = "10.1002/ajh.23897",
language = "English",
volume = "90",
pages = "132--138",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma

AU - and on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation

AU - Kako, Shinichi

AU - Izutsu, Koji

AU - Kato, Koji

AU - Kim, Sung Won

AU - Mori, Takehiko

AU - Fukuda, Takahiro

AU - Kobayashi, Naoki

AU - Taji, Hirofumi

AU - Hashimoto, Hisako

AU - Kondo, Tadakazu

AU - Sakamaki, Hisashi

AU - Morishima, Yasuo

AU - Suzuki, Ritsuro

AU - Suzumiya, Junji

PY - 2015/2/1

Y1 - 2015/2/1

N2 - The optimal treatment strategy with the use of hematopoietic stem cell transplantation (HSCT) for relapsed and refractory Hodgkin lymphoma (HL) remains unclear. We performed a retrospective analysis using registry data from the Japanese Society for Hematopoietic Cell Transplantation. Adult patients with HL who underwent a first autologous or a first allogeneic HSCT between 2002 and 2009 were included. Patients who underwent HSCT in first complete remission (CR) were excluded. Autologous and allogeneic HSCT were performed in 298 and 122 patients, respectively. For autologous HSCT, overall survival at 3 years (3yOS) was 70%, and sex, age, disease status, and performance status (PS) at HSCT were prognostic factors. OS was favorable even in patients who underwent autologous HSCT in disease status other than CR. For allogeneic HSCT, 3yOS was 43%, and sex and PS at HSCT were prognostic factors. Disease status at HSCT, previous autologous HSCT, and conditioning intensity did not affect OS. Moreover, graft-versus-host disease did not affect progression-free survival or relapse/progression rate. A first allogeneic HSCT without a previous autologous HSCT was performed in 40 patients. 3yOS was 45%, and was significantly inferior to that in patients who underwent their first autologous HSCT. This result was retained after the correction by the different patient characteristics according to the type of HSCT. In conclusion, autologous HSCT is effective in prolonging survival in patients with relapsed and refractory HL. Allogeneic HSCT might be beneficial even to relapsed HL after autologous HSCT, although establishing the role of allogeneic HSCT remains a challenge.

AB - The optimal treatment strategy with the use of hematopoietic stem cell transplantation (HSCT) for relapsed and refractory Hodgkin lymphoma (HL) remains unclear. We performed a retrospective analysis using registry data from the Japanese Society for Hematopoietic Cell Transplantation. Adult patients with HL who underwent a first autologous or a first allogeneic HSCT between 2002 and 2009 were included. Patients who underwent HSCT in first complete remission (CR) were excluded. Autologous and allogeneic HSCT were performed in 298 and 122 patients, respectively. For autologous HSCT, overall survival at 3 years (3yOS) was 70%, and sex, age, disease status, and performance status (PS) at HSCT were prognostic factors. OS was favorable even in patients who underwent autologous HSCT in disease status other than CR. For allogeneic HSCT, 3yOS was 43%, and sex and PS at HSCT were prognostic factors. Disease status at HSCT, previous autologous HSCT, and conditioning intensity did not affect OS. Moreover, graft-versus-host disease did not affect progression-free survival or relapse/progression rate. A first allogeneic HSCT without a previous autologous HSCT was performed in 40 patients. 3yOS was 45%, and was significantly inferior to that in patients who underwent their first autologous HSCT. This result was retained after the correction by the different patient characteristics according to the type of HSCT. In conclusion, autologous HSCT is effective in prolonging survival in patients with relapsed and refractory HL. Allogeneic HSCT might be beneficial even to relapsed HL after autologous HSCT, although establishing the role of allogeneic HSCT remains a challenge.

UR - http://www.scopus.com/inward/record.url?scp=84921391884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921391884&partnerID=8YFLogxK

U2 - 10.1002/ajh.23897

DO - 10.1002/ajh.23897

M3 - Article

C2 - 25382792

AN - SCOPUS:84921391884

VL - 90

SP - 132

EP - 138

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -